Search results for "Androgen"

showing 10 items of 326 documents

Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.

2012

Background Hirsutism, defined by the presence of excessive terminal hair in androgen-sensitive areas of the female body, is one of the most common disorders in women during reproductive age. Methods We conducted a systematic review and critical assessment of the available evidence pertaining to the epidemiology, pathophysiology, diagnosis and management of hirsutism. Results The prevalence of hirsutism is ~10% in most populations, with the important exception of Far-East Asian women who present hirsutism less frequently. Although usually caused by relatively benign functional conditions, with the polycystic ovary syndrome leading the list of the most frequent etiologies, hirsutism may be th…

hirsutism; androgen excess; guidelinesmedicine.medical_specialtyPediatricsHirsutismMEDLINETerminal hairAndrogen ExcessSettore MED/13 - EndocrinologiaIntervention (counseling)EpidemiologyMedicineHumansguidelineshirsutismSocieties MedicalHirsutism PCOS Hyperandrogenism Adrenal hyperplasia idiopathic hirsutismGynecologybusiness.industryObstetrics and Gynecologymedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaPolycystic ovaryReproductive Medicinehirsutism androgen excess terminal hair polycystic ovary syndrome guidelinesEtiologyAndrogensFemaleandrogen excessbusinessHair FolliclePolycystic Ovary SyndromeHuman reproduction update
researchProduct

Insulin sensitività in women whit clinical features of hyperandrogenism.

2004

hyperandrogenism
researchProduct

The effects of inositol in the female androgenetic alopecia: preliminary data

2014

inositol androgenetic alopeciaSettore MED/35 - Malattie Cutanee E Veneree
researchProduct

Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate c…

2022

Objectives The aim of this preplanned secondary analysis of a 12-month randomised controlled trial was to investigate the effects of a multicomponent exercise programme combined with daily whey protein, calcium and vitamin D supplementation on cognition in men with prostate cancer treated with androgen deprivation therapy (ADT). Design 12-month, two-arm, randomised controlled trial. Setting University clinical exercise centre. Participants 70 ADT-treated men were randomised to exercise-training plus supplementation (Ex+ Suppl, n=34) or usual care (control, n=36). Intervention Men allocated to Ex + Suppl undertook thrice weekly resistance training with weight-bearing exercise training plus d…

kognitioeturauhassyöpäandrogen deprivation therapyravintoainevalmisteetandrogeenithoito
researchProduct

PGK1-AR axis: Benefits of a novel actor in PCOS pathology.

2020

lcsh:R5-920business.industrylcsh:RMEDLINElcsh:MedicineGeneral MedicineBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyPhosphoglycerate KinaseText miningReceptors AndrogenCommentaryMedicineHumansFemaleDisease Susceptibilitybusinesslcsh:Medicine (General)Polycystic Ovary SyndromeSignal TransductionEBioMedicine
researchProduct

5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety

2020

Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5-alpha reductase (5-AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5-alpha reductase inhibitor (5-ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning ferti…

medicine.drug_classDermatologyReductasePharmacology030207 dermatology & venereal diseases03 medical and health sciences5 Alpha-Reductase Inhibitorchemistry.chemical_compound5-alpha Reductase Inhibitors0302 clinical medicinemedicineHumansTestosteronebusiness.industryFinasterideNeurotoxicityAlopeciaAndrogen AntagonistsGeneral MedicineDutasterideDutasteridemedicine.diseaseAndrogenchemistry030220 oncology & carcinogenesisDihydrotestosteroneFinasteridebusinessmedicine.drugDermatologic Therapy
researchProduct

Comment on “Androgens and women: COVID‐19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism”

2021

medicine.medical_specialty2019-20 coronavirus outbreakHirsutismCoronavirus disease 2019 (COVID-19)business.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MEDLINECOVID-19Dermatologymedicine.diseaseDermatologyCorrespondenceAcne VulgarisAndrogensMedicineHumansFemalebusinesshirsutismAcnePolycystic Ovary SyndromeInternational Journal of Dermatology
researchProduct

Ovarian volume in normal and hyperandrogenic adolescent women

2015

Objective To study the threshold for increased ovarian size during different periods of adolescence. Design Cross sectional study with retrospective analysis. Setting University center. Patient(s) A total of 146 hyperandrogenic adolescent women and 72 healthy adolescent controls. Intervention(s) Intravaginal or transabdominal ovarian sonography. Main Outcome Measure(s) Determination of normal ovarian size during the different phases of adolescence calculated using the ellipsoid formula; calculation of threshold for increased ovarian size during different adolescent gynecologic ages and prevalence of increased ovarian size for hyperandrogenic girls at different gynecologic ages. Result(s) In…

medicine.medical_specialtyAdolescentendocrine system diseasesCross-sectional studyRetrospective analysisHumansMedicineChildRetrospective StudiesUltrasonographyGynecologybusiness.industryOvaryHyperandrogenismAge FactorsOutcome measuresObstetrics and GynecologyOrgan Sizemedicine.diseasePolycystic ovaryCross-Sectional StudiesReproductive MedicineMenarcheFemaleHyperandrogenismbusinessFertility and Sterility
researchProduct

Polycystic ovary syndrome: metabolic consequences and long-term management.

2014

Young women with polycystic ovary syndrome (PCOS) present an increased risk for type II diabetes and cardiovascular diseases. The prevalence of altered glucose tolerance ranges between 20 and 35 % in patients while the prevalence of type II diabetes ranges between 2 and 8 % and seems related to body weight and ethnic group. Moving from the young fertile age to the 40s and the menopause the prevalence of type II diabetes continues to increase compared to the general female population and may reach 10-16 % of PCOS women. However, prevalence of altered glucose tolerance does not increase. Also cardiovascular risk is increased in a large part of young PCOS women but this risk tends to be normal…

medicine.medical_specialtyAgingClinical BiochemistryPhysiologyAge DistributionRisk FactorsInternal medicineLong term managementmedicineHumansIn patientbusiness.industryGeneral Medicinemedicine.diseasePolycystic ovaryObesityAndrogen secretionMenopausePostmenopauseYoung ageEndocrinologyIncreased riskDiabetes Mellitus Type 2Cardiovascular DiseasesFemalebusinessPolycystic Ovary SyndromeScandinavian journal of clinical and laboratory investigation. Supplementum
researchProduct

Endocrinology: Substrate dependency of C19 conjugates in hirsute hyperandrogenic women and the influence of adrenal androgen

1995

Serum C19 conjugates, specifically 3 alpha-androstanediol glucuronide (3 alpha G), reflect peripheral androgen action through the action of 5 alpha-reductase activity. The origin of 5 alpha-reduced C19 conjugates has been controversial and it has been suggested that they are derived primarily from adrenal androgens. We examined concentrations of 3 alpha G, 3 alpha-androstanediol sulphate (3 alpha S), androsterone glucuronide (AoG) and androsterone sulphate (AoS) in 40 hirsute hyperandrogenic women. These patients were divided into four groups based upon individual, combined or normal concentrations of the adrenal androgens dehydroepiandrosterone (DHEAS) and 11 beta-hydroxy-androstenedione. …

medicine.medical_specialtyAndrosteroneAndrosterone glucuronideAdrenal cortexmedicine.drug_classRehabilitationHyperandrogenismObstetrics and GynecologyDehydroepiandrosteronemedicine.diseaseAndrogenchemistry.chemical_compoundEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryInternal medicinemedicineAndrostenedioneTestosteroneHuman Reproduction
researchProduct